NIFTY  9,351.85  0.49%
  SENSEX  30,133.30  0.63%
 CURRENCY  Rs  64.28/$ 70.28/€, 82.54/£
  GOLD  28,734.00  -0.28%
  SILVER  40,200.00  -0.53%
  DAX  12,467.00  0.10%
  FTSE  7,275.64  0.15%
  CAC  5,277.88  0.15%
  HANG SENG  24,578.40  0.50%
  NIKKEI  19,289.40  1.10%
  Shanghai Composite  3,140.85  0.10%
  DOW JONES  20,996.10  1.12%
  NASDAQ  6,025.49  0.70%
  S&P 500  2,388.61  0.61%
LAKSHMI VILAS BANK : Q4 PAT At Rs 52.1 Cr Vs Rs 49 Cr, Up 6.3% YoY LAKSHMI VILAS BANK : Q4 Provisions At Rs 108 Cr Vs Rs 27.1 Cr YoY LAKSHMI VILAS BANK : Q4 Gross NPA At 2.67% Vs 2.78% QoQ LAKSHMI VILAS BANK : Q4 Net NPA At 1.76% Vs 1.82% QoQ LAKSHMI VILAS BANK : To Pay Rs 2.70/Share As Dividend

U.S. FDA Relief For Ranbaxy

Video:

Play this video

March 28: Bloomberg reports that the U.S. FDA has disputed a study of generic heart drugs by Preston Mason. The regulator said generics from overseas are safe, as it did not find contaminants in samples obtained through retail pharmacies. The stock of Ranbaxy today took heart from that news and shot up by 4% in intraday trade. Priya Sheth shares a detailed report on the same.